| FDA Panel to Consider Rivaroxaban's Comparative Efficacy - Family Practice News Digital Network |
|
|
Family Practice News Digital Network The Food and Drug Administration's policy requiring new drugs for serious conditions to be "as effective" as approved agents will take center stage at the Cardiovascular and Renal Drugs Advisory Committee's Sept. 8 review of Bayer/Johnson & Johnson's |